Last update April 22, 2026

炔雌醇

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Synthetic estrogen that has a similar action as estradiol. Used in combination with progestogens for contraception. Daily oral administration.

ESTROGEN and related drugs are excreted into the breast milk in no or small amount.

Its pharmacokinetic data (high percentage of protein binding and very wide volume of distribution) explain the negligible or null passage into breast milk observed. (Segev 2025, Betrabet 1986, Nilsson 1978)

For a detailed discussion of the potential issues associated with the use of combined estrogen-progestin contraceptives, the possible decrease in milk production caused by estrogen use, and why progestin-only contraceptives are preferred during breastfeeding, see below: : “(Combined Estrogen + Progestin Contraceptives, COCs)”


See below the information of this related product:

Alternatives

We do not have alternatives for 炔雌醇.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

炔雌醇 is Ethinylestradiol in Chinese.

Is written in other languages:

Groups

炔雌醇 belongs to these groups or families:

Tradenames

Main tradenames from several countries containing 炔雌醇 in its composition:

List of 11 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 40 - 60 %
Molecular weight 296 daltons
Protein Binding 99 %
VD oral: 5 - 10; topic: 169 l/Kg
pKa 10.33 -
Tmax oral: 1.5 ± 0.5; topic: 86 ±31 hours
T½ oral: 8 ± 5; topic: 28 ± 34 hours
M/P ratio 0.3 -
Theoretical Dose 0. 0 - 0.000045 mg/Kg/d
Relative Dose 0 - 0.54 %

References

  1. Segev L, Ben Zimra A, Weitzman GA, Bloch N, Pitussi I, Alkhazov T, Kogan NM, Peleg D, Samson AO, Ben Shachar I. Ethinylestradiol Transfer into Breast Milk of Women Using Low-Dose Combined Hormonal Contraception Is Negligible. Open Access J Contracept. 2025 Dec 10;16:189-197. Abstract Full text (link to original source)
  2. Betrabet SS, Shikary ZK, Toddywalla VS, Patel D, Vaidya P, Saxena BN. ICMR Task Force Study on hormonal contraception. Biological activity of ethinyl estradiol present in the breast milk. Contraception. 1986 Abstract
  3. Klinger G, Claussen C, Schröder S. [Excretion of ethinyloestradiol sulfonate in the human milk (author's transl)]. Zentralbl Gynakol. 1981 Abstract
  4. Nilsson S, Nygren KG, Johansson ED. Ethinyl estradiol in human milk and plasma after oral administration. Contraception. 1978 Abstract

Total visits

3,832

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child´s Health in Greece

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM